Skip to content
10-K

Annual Report

REGENERX BIOPHARMACEUTICALS, INC.

0001410578-23-000628

← back to feed
Filed
Apr 11, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2022 · Mar 17, 2023 143.55M sh
Shares Diluted FY 2022 · Dec 31, 2022 143.55M sh
Shares Diluted FY 2022 · Dec 31, 2021 138.59M sh
Operating Cash Flow FY 2022 · Dec 31, 2022 −$940.72K
Operating Cash Flow FY 2022 · Dec 31, 2021 −$990.3K
Cash And Equivalents FY 2022 · Dec 31, 2022 $290.89K
Cash And Equivalents FY 2022 · Dec 31, 2021 $1.23M
Stockholders Equity FY 2022 · Dec 31, 2022 −$3.45M
Stockholders Equity FY 2022 · Dec 31, 2021 −$2.23M
Stockholders Equity FY 2022 · Dec 31, 2020 −$2.82M
Current Liabilities FY 2022 · Dec 31, 2022 $553.67K
Current Liabilities FY 2022 · Dec 31, 2021 $429.93K
Total Liabilities FY 2022 · Dec 31, 2022 $3.83M
Total Liabilities FY 2022 · Dec 31, 2021 $3.51M
Current Assets FY 2022 · Dec 31, 2022 $306.92K
Current Assets FY 2022 · Dec 31, 2021 $1.25M
Total Assets FY 2022 · Dec 31, 2022 $382.18K
Total Assets FY 2022 · Dec 31, 2021 $1.28M
Eps Diluted FY 2022 · Dec 31, 2022 −$0.01
Eps Diluted FY 2022 · Dec 31, 2021 −$0.01
Eps Basic FY 2022 · Dec 31, 2022 −$0.01
Eps Basic FY 2022 · Dec 31, 2021 −$0.01
Sga Expense FY 2022 · Dec 31, 2022 $1.48M
Sga Expense FY 2022 · Dec 31, 2021 $1.4M
Rd Expense FY 2022 · Dec 31, 2022 $0
Rd Expense FY 2022 · Dec 31, 2021 $6.64K
Net Income FY 2022 · Dec 31, 2022 −$1.73M
Net Income FY 2022 · Dec 31, 2021 −$1.6M
Operating Income FY 2022 · Dec 31, 2022 −$1.4M
Operating Income FY 2022 · Dec 31, 2021 −$1.33M
Revenue FY 2022 · Dec 31, 2022 $76.76K
Revenue FY 2022 · Dec 31, 2021 $76.76K
Cost Of Revenue FY 2022 · Dec 31, 2010 $25K